<?xml version="1.0" encoding="iso-8859-1" ?>
<rss version="2.0" xmlns:s="http://resources.bnet.com/">
<channel>
	<title><![CDATA[Progenics Pharmaceuticals Inc. | Company News & Executive Profiles - PGNX | BNET]]></title>
	<link><![CDATA[http://resources.bnet.com/topic/progenics+pharmaceuticals+inc..html?i=11]]></link>
	<description><![CDATA[Latest company news & analysis, recent events, stock quotes, earning call transcripts, with profiles and descriptions of top business executives for Progenics Pharmaceuticals Inc.]]></description>
	<s:counts start="0" returned="3" found="3" />
	<language>en-us</language>
	<item>
		<title><![CDATA[A Possible New Indication for Progenix's Relistor Could Revive Its Fortunes]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F174487-a-possible-new-indication-for-progenix-s-relistor-could-revive-its-fortunes%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[David Greene submits: On Wednesday (Nov. 18), Progenic's Pharmaceutical PGNX, received some good news in the form of a Reuters story stating that the widely-used painkiller drug, morphine, may actually accelerate cancer growth in patients. Researchers in the US have results from two studies that show that morphine could be...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Fri, 20 Nov 2009 03:07:33 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/david+greene.html"><![CDATA[David Greene]]></category>
		<category domain="http://resources.bnet.com/topic/progenics+pharmaceuticals+inc..html"><![CDATA[Progenics Pharmaceuticals Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">PGNX</category>
		<category domain="tickers">PGNX</category>
	</item>
	<item>
		<title><![CDATA[Wyeth and Progenics Receive Approval from European Commission for RELISTOR for Opioid-Induced Constipation in Advanced Illness Patients]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_July_3/ai_n27889341]]></link>
		<description><![CDATA[COLLEGEVILLE, Pa., & TARRYTOWN, N.Y. -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), and Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX), today announced that the companies have received marketing approval for RELISTOR[TM] methylnaltrexone bromide subcutaneous injection from the European Commission. RELISTOR is now approved in the 27 member states of the...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Thu, 03 Jul 2008 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/company.html"><![CDATA[Company]]></category>
		<category domain="http://resources.bnet.com/topic/editor.html"><![CDATA[Editor]]></category>
		<category domain="http://resources.bnet.com/topic/european+commission.html"><![CDATA[European Commission]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[HEALTHCARE]]></category>
		<category domain="http://resources.bnet.com/topic/patient.html"><![CDATA[patient]]></category>
		<category domain="http://resources.bnet.com/topic/progenics+pharmaceuticals+inc..html"><![CDATA[Progenics Pharmaceuticals Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/software.html"><![CDATA[SOFTWARE]]></category>
		<category domain="http://resources.bnet.com/topic/therapy.html"><![CDATA[therapy]]></category>
		<category domain="http://resources.bnet.com/topic/wyeth.html"><![CDATA[Wyeth]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">PGNX</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">WYE</category>
		<category domain="tickers">PGNX,WYE</category>
	</item>
	<item>
		<title><![CDATA[WYETH/PROGENICS START PHASE 2 TRIAL OF ORAL METHYLNALREXONE.]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb6494/is_200610/ai_n25837006]]></link>
		<description><![CDATA[Wyeth Pharmaceuticals, a division of Wyeth (NYSE:WYE), and  Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) have initiated a phase 2  clinical trial to evaluate once-daily dosing of oral methylnaltrexone.  This trial is designed to identify the doses of methylnaltrexone to be  taken forward into the phase 3 clinical studies...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Sun, 01 Oct 2006 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/progenics+pharmaceuticals+inc..html"><![CDATA[Progenics Pharmaceuticals Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/wyeth.html"><![CDATA[Wyeth]]></category>
		<category domain="http://resources.bnet.com/topic/wyeth+pharmaceuticals+inc..html"><![CDATA[Wyeth Pharmaceuticals Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">PGNX</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">WYE</category>
		<category domain="tickers">PGNX,WYE</category>
	</item>
</channel>
</rss>
